Table 1.
General demographic details for the prospective dataset.
| Site 1 | Site 2 | Site 3 | Site 4 | All Sites | |
|---|---|---|---|---|---|
| Patients tested | 675 | 375 | 498 | 584 | 2132 |
| Gender | |||||
| Male | 322 (47.7%) | 155 (41.3%) | 264 (53.0%) | 281 (48.1%) | 1022 (47.9%) |
| Female | 353 (52.3%) | 220 (58.7%) | 234 (47.0%) | 303 (51.9%) | 1110 (52.1%) |
| Age (yrs) | |||||
| 0–1 | 105 (15.6%) | 25 (6.7%) | 155 (31.1%) | 168 (28.8%) | 453 (21.2%) |
| >1–5 | 66 (9.8%) | 22 (5.9%) | 92 (18.5%) | 70 (12.0%) | 250 (11.7%) |
| >5–21 | 87 (12.9%) | 73 (19.5%) | 101 (20.3%) | 92 (15.8%) | 353 (16.6%) |
| >21–65 | 174 (25.8%) | 152 (40.5%) | 111 (22.3%) | 147 (25.2%) | 584 (27.4%) |
| >65 | 243 (36.0%) | 103 (27.5%) | 39 (7.8%) | 107 (18.3%) | 492 (23.1%) |
| Subject Status | |||||
| Outpatients | 309 (45.8%) | 157 (41.9%) | 49 (9.8%) | 39 (6.7%) | 554 (26.0%) |
| Hospitalized | 255 (37.8%) | 144 (38.4%) | 332 (66.7%) | 329 (56.3%) | 1060 (49.7%) |
| Emergency Department | 111 (16.4%) | 74 (19.7%) | 117 (23.5%) | 216 (37.0%) | 518 (24.3%) |
| Immune Status | |||||
| Immunocompromised | 116 (17.2%) | 89 (23.7%) | 0 (0.0%) | 59 (10.1%) | 264 (12.4%) |
| Immunocompetent | 506 (75.0%) | 285 (76.0%) | 0 (0.0%) | 525 (89.9%) | 1316 (61.7%) |
| Not Determined | 53 (7.9%) | 1 (0.3%) | 498 (100%) | 0 (0.0%) | 552 (25.9%) |